Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy, NCT07547033
Summary
A randomized clinical trial comparing the SMA-first (artery-first) surgical technique with conventional pancreaticoduodenectomy (Whipple procedure) in patients with pancreatic adenocarcinoma and pancreatic head cancer. The trial will assess whether the artery-first approach, which exposes the superior mesenteric artery early during surgery, enables more complete tumor removal and reduces local cancer recurrence rates. Both interventions involve peri-adventitial dissection with either right posterior/anterior or antero-posterior approaches at specialized hospitals.
“This research protocol aims to compare this artery-first technique with the standard surgical approach.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This document registers a new randomized controlled clinical trial on ClinicalTrials.gov comparing two surgical approaches to pancreaticoduodenectomy (Whipple procedure) for pancreatic head cancers. The SMA-first approach involves early isolation and dissection of the superior mesenteric artery before any irreversible surgical steps, whereas the conventional approach uses an antero-posterior method after pancreatic section.
Healthcare institutions and surgical teams conducting pancreatic cancer research may use this registry entry as reference for trial design, outcome measures, and inclusion criteria. Patients with pancreatic ductal adenocarcinoma or pancreatic head cancer seeking clinical trial participation can access enrollment information through ClinicalTrials.gov. The study's findings, upon completion, may inform evidence-based surgical standards for pancreaticoduodenectomy.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy
N/A NCT07547033 Kind: NA Apr 23, 2026
Abstract
"Pancreatic cancer, especially pancreatic ductal adenocarcinoma, is one of the most serious and deadly cancers. Its outlook is very poor, with fewer than 10% of patients surviving five years after diagnosis. This is largely because the disease is often discovered at a late stage and because it frequently comes back even after surgery.
When the tumor is located in the head of the pancreas, the only treatment that can potentially cure the disease is a major operation called a pancreaticoduodenectomy, also known as the Whipple procedure. This surgery is now safely performed in specialized hospitals, but it remains complex and carries a high risk of complications. Importantly, even after surgery, cancer cells often remain, leading to a high rate of local recurrence.
A newer surgical technique, known as the "artery-first" approach, changes the order of the operation. By carefully exposing a major blood vessel near the pancreas at the beginning of the surgery, surgeons can better assess whether the tumor can be completely removed and can improve the precision of the operation.
This research protocol aims to compare this artery-first technique with the standard surgical approach. The goal is to determine whether starting the operation by addressing the artery allows for more complete tumor removal and reduces the risk of cancer coming back in patients with pancreatic cancer of the head of the pancreas."
Conditions: Pancreatic Adenocarcinoma, Pancreatic Head Cancer
Interventions: SMA-first pancreaticoduodenectomy using either right posterior or anterior approach. SMA identified and isolated with peri-adventitial dissection before any irreversible section., Conventional pancreaticoduodenectomy without prior isolation of the SMA; antero-posterior approach of the uncinate process after pancreatic section.
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.